Robert Lucas, director, quality compliance, regulatory and auditing, Verista, discusses why life sciences leaders must rethink compliance as an integrated, continuously managed discipline to keep pace with evolving regulatory expectations.
Upperton has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has approved a variation to its existing Manufacturing and Importation Authorisation for Investigational Medicinal Products (MIA(IMP)) licence.
In August 2026, the European Union’s (EU's) Packaging and Packaging Waste Regulation (PPWR) took direct effect across all member states. Claudia Anzaldo and Véronique Boscher at ICON plc discuss.
Jason Bryant, general manager of AI platforms at ArisGlobal, and Samuel Wallis, head of case processing at Bristol Myers Squibb, argue that pharmacovigilance teams need a formal measure of trust in validated AI systems.
At the Veeva R&D and Quality Summit, Olivia Friett spoke with Crystal Allard, senior director of government strategy at Veeva Systems, about the growing role of AI in life sciences and the regulatory considerations shaping its adoption.
Christian Dunne, director of global corporate business development, ChargePoint Technology explores a risk-based response to evolving Annex 1 expectations.
Megha Sinha, founder and CEO of Kamet Consulting Group explains why the systems most manufacturers use to manage post-approval changes are no longer fit for purpose, and what a viable alternative looks like in the AI age.
Minister for Enterprise, Tourism and Employment Peter Burke, and representatives from IDA Ireland, visited Athlone Laboratories to consult with key figures on a vision for Ireland’s future in the domestic manufacturing of critical medicines.
